Filter Results:
(926)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
- 2024
- Working Paper
Dusting Off the Old Ones: Drug Licensing to Startups, Innovation Success and Efficiency
By: Mosab Hammoudeh, Joshua Lev Krieger and Jiajie Xu
This paper investigates whether moving R&D from incumbents to startups can increase innovation. Using comprehensive drug development data, we examine the outcomes of drug projects licensed from large firms to startups. We find that these projects licensed to startups... View Details
Keywords: Product Development; Innovation and Invention; Business Startups; Research and Development; Performance Efficiency; Pharmaceutical Industry
Hammoudeh, Mosab, Joshua Lev Krieger, and Jiajie Xu. "Dusting Off the Old Ones: Drug Licensing to Startups, Innovation Success and Efficiency." Harvard Business School Working Paper, No. 24-067, March 2024.
- March 2023 (Revised March 2024)
- Case
The Purdue Pharma Bankruptcy: Settling the Opioid Crisis
By: Kristin Mugford, Carin-Isabel Knoop and Susan Pinckney
How to get to a fair outcome for claimants in the Purdue Pharma bankruptcy given its significant role in the U.S. opioid crisis. View Details
Keywords: Regulation; Ethics; Fairness; Insolvency and Bankruptcy; Government Legislation; Courts and Trials; Laws and Statutes; Lawsuits and Litigation; Legal Liability; Crime and Corruption; Negotiation Offer; Negotiation Participants; Negotiation Style; Product Design; Product Development; Brands and Branding; Marketing Strategy; Trust; Government and Politics; Law; Negotiation; Operations; Ownership; Marketing; Social Psychology; Health Care and Treatment; Pharmaceutical Industry; United States
Mugford, Kristin, Carin-Isabel Knoop, and Susan Pinckney. "The Purdue Pharma Bankruptcy: Settling the Opioid Crisis." Harvard Business School Case 223-060, March 2023. (Revised March 2024.)
- 2021
- Working Paper
Regulatory Approval and Expanded Market Size
By: Benjamin Berger, Amitabh Chandra and Craig Garthwaite
Regulatory review of new medicines is often viewed as a hindrance to innovation by increasing the hurdle to bring products to market. However, a more complete accounting of regulation must also account for its potential market expanding effects through quality... View Details
Keywords: New Medicines; Regulatory Approval; Health Care and Treatment; Research and Development; Governing Rules, Regulations, and Reforms; Markets; Expansion; Pharmaceutical Industry
Berger, Benjamin, Amitabh Chandra, and Craig Garthwaite. "Regulatory Approval and Expanded Market Size." NBER Working Paper Series, No. 28889, June 2021.
- October 1996 (Revised February 1997)
- Case
Upjohn Company, The: The Upjohn-Pharmacia Merger
By: Krishna G. Palepu and Amy P. Hutton
In August 1995, the Upjohn Co. and Pharmacia AB announced a "merger of equals." This case provides background information on the industry, the position of Upjohn, and Upjohn's rationale for the proposed merger. View Details
Keywords: Mergers and Acquisitions; Financial Statements; Business Strategy; Annual Reports; Pharmaceutical Industry
Palepu, Krishna G., and Amy P. Hutton. "Upjohn Company, The: The Upjohn-Pharmacia Merger." Harvard Business School Case 197-034, October 1996. (Revised February 1997.)
- May 2013
- Teaching Plan
China Novartis Institute for Biomedical Research: Building a Sustainable, Globally Integrated Research Enterprise
By: Vicki Sato and Annelena Lobb
Sato, Vicki, and Annelena Lobb. "China Novartis Institute for Biomedical Research: Building a Sustainable, Globally Integrated Research Enterprise." Harvard Business School Teaching Plan 613-103, May 2013.
- November 2012
- Teaching Note
On Weldon's Watch: Recalls at Johnson & Johnson from 2009 to 2010 (TN)
By: Sandra J. Sucher and Clayton S. Rose
Teaching Note for On Weldon's Watch: Recalls at Johnson & Johnson from 2009 to 2010 HBS case 311-029. View Details
- June 2010 (Revised April 2017)
- Teaching Note
Pfizer: Letter from the Chairman (A) and (B)
By: Robert Simons and Kathryn Rosenberg
Teaching Note for 110003 and 110004. View Details
- May 2010 (Revised June 2010)
- Supplement
Pfizer: Letter from the Chairman (B)
By: Robert L. Simons and Kathryn Rosenberg
This case continues the story begun in "Pfizer: A Letter from the Chairman" (HBS No. 110-003), revealing the letter Chairman and CEO Jeff Kindler wrote for the 2008 Annual Report. View Details
Keywords: Corporate Accountability; Corporate Governance; Business and Shareholder Relations; Value Creation; Decision Choices and Conditions; Annual Reports; Pharmaceutical Industry; United States
Simons, Robert L., and Kathryn Rosenberg. "Pfizer: Letter from the Chairman (B)." Harvard Business School Supplement 110-004, May 2010. (Revised June 2010.)
- January 1991 (Revised August 1992)
- Case
Race to Develop Human Insulin
Describes the race to develop human insulin. View Details
Brandenburger, Adam M., Vijay Krishna, and Paul Barese. "Race to Develop Human Insulin." Harvard Business School Case 191-121, January 1991. (Revised August 1992.)
- 1996
- Chapter
The Determinants of Research Productivity in Ethical Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
- July 2008 (Revised August 2008)
- Teaching Note
Recent Developments in the Ranbaxy Case (TN)
By: Robert C. Pozen
Teaching Note for [609010]. View Details
- May 2008
- Teaching Note
Michael Fernandes at Nicholas Piramal (TN)
By: Michel Anteby and Nitin Nohria
Teaching Note for [408-001]. View Details
- November 2006 (Revised May 2007)
- Supplement
Corporate Venture Capital at Eli Lilly
Hamermesh, Richard G. "Corporate Venture Capital at Eli Lilly." Harvard Business School Video Supplement 807-705, November 2006. (Revised May 2007.)
- September 2006
- Supplement
Wu Xi Pharmatech
Keywords: Pharmaceutical Industry
Hamermesh, Richard G. "Wu Xi Pharmatech." Harvard Business School Video Supplement 807-701, September 2006.
- June 2006 (Revised January 2012)
- Supplement
Teena Lerner: Dividing the Pie at Rx Capital (B)
By: Boris Groysberg and Robin Abrahams
Groysberg, Boris, and Robin Abrahams. "Teena Lerner: Dividing the Pie at Rx Capital (B)." Harvard Business School Supplement 406-112, June 2006. (Revised January 2012.)
- June 2006
- Teaching Note
Vertex Pharmaceuticals: R&D Portfolio Management (A), (B), and (C) (TN)
By: Francesca Gino and Gary P. Pisano
- February 2006 (Revised February 2009)
- Case
AIDS in Brazil
By: Rohit Deshpande and Ricardo Reisen de Pinho
Abbott Labs has reached an impasse with the Brazilian government in negotiations over the pricing of a new anti-AIDS drug, Kaletra. The Brazilian government threatens compulsory licensing unless Abbott drastically reduces the price of Kaletra. View Details
Keywords: Price; Government and Politics; Health Care and Treatment; Health Disorders; Rights; Negotiation; Business and Government Relations; Pharmaceutical Industry; Brazil
Deshpande, Rohit, and Ricardo Reisen de Pinho. "AIDS in Brazil." Harvard Business School Case 506-062, February 2006. (Revised February 2009.)
- February 2002
- Case
NeuroTherapy Ventures: Catalyzing Neurologic Innovations
Discusses the impact of limited market size on epilepsy therapies and shows how an early-stage venture fund can catalyze faster development of new treatments. View Details
Keywords: Information Technology; Commercialization; Innovation and Management; Business Startups; Pharmaceutical Industry
Chesbrough, Henry W. "NeuroTherapy Ventures: Catalyzing Neurologic Innovations." Harvard Business School Case 602-124, February 2002.
- October 2000
- Supplement
Hans Fritz at Novartis Thailand (D): The First 18 Months
By: Michael Y. Yoshino and Carin-Isabel Knoop
Supplements the (A) case. View Details
Yoshino, Michael Y., and Carin-Isabel Knoop. "Hans Fritz at Novartis Thailand (D): The First 18 Months." Harvard Business School Supplement 301-055, October 2000.